Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AloCELYVIR in DIPG and Medulloblastoma
NCT04758533Phase 2Active, not recruiting
- Sponsor
- Hospital Universitario Niño Jesús
- Start
- Apr 2021
- Primary completion
- Apr 2026
- Modality
- Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AloCelyvir in diffuse intrinsic pontine glioma (DIPG) and medulloblastoma, sponsored by Hospital Universitario Niño Jesús. Primary endpoint: Dose-Limiting Toxicities rate at 1 Month. Started Apr 2021; status: active, not recruiting.
02
Drugs
AloCelyvir
03
Conditions
diffuse intrinsic pontine glioma (DIPG)medulloblastoma
Beyond the preview
Go deeper on NCT04758533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758533.